Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomyMeera R. Chappidi, Trinity J. Bivalacqua, Max Kates et al.|Urologic Oncology Seminars and Original Investigations|2016Cited by 130
Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate–Risk Prostate Cancer in the US Between 2010 and 2018Bashir Al Hussein Al Awamlh, Jonathan E. Shoag, Alec Zhu et al.|JAMA Internal Medicine|2023Cited by 29
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancerHunter S. Robinson, Jeffrey J. Tosoian, Sangmyung S. Lee et al.|Prostate Cancer and Prostatic Diseases|2024Cited by 19
Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non–Digital Rectal Examination UrineJeffrey J. Tosoian, Arul M. Chinnaiyan, Yuping Zhang et al.|The Journal of Urology|2025Cited by 13
Point of View: Innovation and Progress for Screening and Management of Localized Prostate Cancer: What an Exciting TimeJeffrey J. Tosoian, Wayne Brisbane, Alice Yu|The Journal of Urology|2023Cited by 0